Recombinant hiv env polypeptides and their uses

Patent metadata

Field	Value
Publication number	US-2025059238-A1
Application number	US-201917299062-A
Country	US
Kind code	A1
Filing date	Dec 3, 2019
Priority date	Dec 3, 2018
Publication date	Feb 20, 2025
Grant date	—

Abstract

The present disclosure relates to recombinant HIV Env polypeptides and their use in the treatment and prevention of HIV/AIDS.

First claim

1 - 66 . (canceled)

67 . An engineered or non-naturally occurring HIV Env polypeptide, wherein
a) the engineered or non-naturally occurring HIV Env polypeptide is missing glycan sequons at N156 and N130 and has one or more basic residues at positions 168 to 171, wherein the HIV Env polypeptide; or b) the engineered or non-naturally occurring HIV Env polypeptide is an engineered or non-naturally occurring ZM233 HIV Env polypeptide missing glycan sequons at N156 and N130, wherein the HIV Env polypeptide positions correspond to the HXB2 reference (SEQ ID NO: 1).

68 . The engineered or non-naturally occurring HIV Env polypeptide of claim 67 , which binds to an HIV broadly neutralizing antibody (bnAb) directed to the V2 apex region of HIV envelope.

69 . The engineered or non-naturally occurring HIV Env polypeptide of claim 67 , which is a chimeric HIV Env polypeptide comprising an HIV Env polypeptide backbone and the V1V2 region of the ZM233 HIV Env polypeptide,

70 . The engineered or non-naturally occurring HIV Env polypeptide of claim 69 , wherein the V1V2 region of the ZM233 HIV Env polypeptide comprises the amino acid sequence of SEQ ID NO: 9.

71 . The engineered or non-naturally occurring HIV Env polypeptide of claim 69 , wherein the HIV Env polypeptide backbone comprises a BG505, ZM197, or CFR250 backbone.

72 . The engineered or non-naturally occurring HIV Env polypeptide of claim 67 , which is a chimeric HIV Env polypeptide comprising an HIV Env polypeptide backbone and the amino acid residues of the ZM233 HIV Env polypeptide corresponding to positions about 131 to about 196.

73 . The engineered or non-naturally occurring HIV Env polypeptide of claim 72 , wherein the HIV Env polypeptide backbone comprises a BG505, ZM197, or CFR250 backbone.

74 . The engineered or non-naturally occurring HIV Env polypeptide of claim 67 , which comprises a complex of gp120 and gp41 or a stabilized trimer, optionally wherein the trimer is a SOSIP, NFL, or UFO trimer.

75 . The engineered or non-naturally occurring HIV Env polypeptide of claim 67 , which comprises a V2 apex epitope of ZM233 Env.

76 . The HIV Env polypeptide of claim 75 ,
(a) which comprises basic amino acid substitutions at positions 168 to 171, wherein the HIV Env polypeptide positions correspond to the HXB2 reference, (b) wherein the V2 apex region of positions 156 to 175 comprises one glycan and four consecutive basic amino acids, or (c) wherein the amino acid sequence of ICSFNMTTELRDKKRKVNVL (SEQ ID NO: 11) at positions 156 to 175.

77 . The engineered or non-naturally occurring HIV Env polypeptide of claim 67 comprising the amino acid sequence of I-C-X 1 -F-N-X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -X 10 -X 11 -X 12 -V-N-V-L (SEQ ID NO: 10) at positions 156 to 175,
wherein X 1 comprises S, T, N, or F; X 2 comprises I, V, T, Q, of M; X 3 comprises S or T; X 4 comprises S or T; X 5 comprises S, E, or G; X 6 comprises I, L, or V; X 7 comprises K or R; X 8 comprises G or D; X 9 comprises K, R, E, or Q; X 10 comprises K, R, E, or Q; X 11 comprises K, R, E, or Q; and X 12 comprises K, E, or Q,

78 . The engineered or non-naturally occurring HIV Env polypeptide of claim 77 , wherein at least three of X9, X10, X11, and X12 comprise basic amino acid residues, all of X9, X10, X11, and X12 comprise basic amino acid residues, or X9, X10, X11, and X12 comprise K.

79 . A nucleic acid molecule encoding the engineered or non-naturally occurring HIV Env polypeptide of claim 67 .

80 . A vector comprising a regulatory element operable in a eukaryotic cell operably linked to the nucleic acid molecule of claim 79 ,

81 . The vector of claim 80 , wherein the vector comprises AAV.

82 . A method of eliciting an immune response or stimulating of a broadly neutralizing HIV antibody (bnAb) in a mammal comprising administering
a) at least one engineered or non-naturally occurring HIV Env polypeptide of claim 67 ; b) a nucleic acid molecule encoding at least one engineered or non-naturally occurring HIV Env polypeptide of claim 67 ; or c) a vector comprising a nucleic acid molecule encoding at least one engineered or non-naturally occurring HIV Env polypeptide of claim 67 .

83 . The method of claim 82 , wherein the engineered or non-naturally occurring HIV Env polypeptide comprises a V2 apex epitope of ZM233 trimer.

84 . A chimeric HIV Env polypeptide comprising an HIV Env polypeptide backbone and
a) the V1V2 region of the ZM233 HIV Env polypeptide; or b) the amino acid residues of the ZM233 HIV Env polypeptide corresponding to positions about 131 to about 196, wherein the HIV Env polypeptide positions correspond to the HXB2 reference.

85 . An HIV Env polypeptide comprising the amino acid sequence of SEQ ID NO: 6, 7, or 8.

86 . A method of engineering an immunogen capable of eliciting a broadly neutralizing antibody (bnAb) against a V2 epitope of an immunodeficiency virus which comprises a) identifying a V2 epitope conserved across two different HIV viruses, b) selecting or designing an antibody that binds to the epitope, and c) designing an immunogen that comprises the V2 epitope and binds to the germline or germline reverted antibody.

Assignees

• Burton Dennis R
• Andrabi Raiees
• Int Aids Vaccine Initiative
• Scripps Research Inst

Inventors

• Burton Dennis R
• Andrabi Raiees

Classifications

• C12N2740/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2740/16122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• A61K39/21

  Retroviridae, e.g. equine infectious anemia virus · CPC title

• A61P31/18

  for HIV · CPC title

• A61K2039/70

  Multivalent vaccine · CPC title